A retrospective study examined the relationship between the ratio of uric acid to high-density lipoprotein cholesterol (UHR) and the likelihood of breast cancer in 500 women, of whom 279 had breast cancer and 221 had benign nodules. The researchers found that the UHR level was significantly higher in the breast cancer group than in the benign disease group (0.10 ± 0.04 vs. 0.09 ± 0.03). The analysis showed that for every 100-unit increase in UHR, the risk of developing breast cancer increased by 9 to 13 percent, and for women with a UHR ≥ 0.091, the risk increased by 63 percent. Although UHR showed moderate diagnostic efficiency with a sensitivity of 80 percent, the analysis confirmed a positive linear correlation between UHR level and breast cancer risk without an effect threshold. The researchers concluded that UHR could help predict the risk of breast cancer, but further studies on larger groups will be needed to confirm these findings.